1. Inicio
  2. Publicaciones
  3. Haematopoietic stem cell transplant in cutaneous T-cell lymphomas: A multicentre propensity-score matched study.

Haematopoietic stem cell transplant in cutaneous T-cell lymphomas: A multicentre propensity-score matched study.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Bejarano L
  • Grau-Pérez M
  • Paíno-Román M
  • Muret MPG
  • Morillo M
  • Muniesa C
  • Torre-Castro J
  • Estrach MT
  • Díez EA
  • Belloso RML
  • Peñate Y
  • Martínez-Mera C
  • Eceiza MJM
  • Ortiz Romero PL
  • Blanes M
  • Fernández-de-Misa R
  • Prieto-Torres L
  • Amer MEP
  • Iznardo H
  • Moreno-Vílchez C
  • Servitje O
  • García-Doval I
  • Cañueto J

Grupos

Abstract

BACKGROUND: Advanced cutaneous T-cell lymphomas (CTCL) are rare, generally refractory to therapeutic options, and have a poor prognosis. Haematopoietic stem cell transplantation (HSCT), mainly allogeneic HSCT (allo-HSCT), is considered a potentially curative option in CTCL refractory to other therapies. However, around half of patients relapse, and allo-HSCT is associated with significant adverse events. The available evidence on the usefulness of HSCT in CTCL generally comes from isolated cases and case series with a limited number of patients. OBJECTIVE: Our aim was to evaluate the outcome of patients undergoing HSCT for advanced primary CTCL in Spain in a real-world environment and to compare their survival with that of similar patients who did not receive HSCT. METHODS: We performed a retrospective observational study nested within the Primary Cutaneous Lymphoma Registry (RELCP) of the Spanish Academy of Dermatology and Venereology, collecting data on all patients receiving HSCT. Then, we performed propensity score matching (PSM) to pair HSCT patients with non-HSCT patients, adjusting for diagnosis, highest disease stage and age at diagnosis. We then performed survival analysis by means of Cox regression. RESULTS: Of 2848 patients included in the RELCP, 51 patients underwent HSCT. Thirty-six patients (70.6%) achieved a complete response and seven patients (13.7%) partial response. Relapse was developed by 56.9% of patients, and 39.2% died (19.6% due to disease progression and 15.7% due to HSCT complications, mainly graft-versus-host disease (GVHD) and sepsis). Overall survival (OS) after HSCT at 5 years was 58.9%. No differences in OS were found between HSCT and non-HSCT groups. CONCLUSIONS: We did not observe a survival benefit among HSCT patients compared to non-HSCT patients within the RELCP cohort. This could be due to patients having received a mean of 6.3 lines of treatment before HSCT. Larger studies might help identify subgroups of patients who might benefit from HSCT.

© 2025 European Academy of Dermatology and Venereology.

Datos de la publicación

ISSN/ISSNe:
0926-9959, 1468-3083

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY  WILEY

Tipo:
Article
Páginas:
99-108
PubMed:
40065681
Enlace a otro recurso:
www.scopus.com
Factor de Impacto:
1,613 SCImago ℠
Cuartil:
Q1 SCImago ℠

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Adult; Aged; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Propensity Score; Retrospective Studies; Skin Neoplasms; Spain; tumor necrosis factor receptor superfamily member 8; adult; Article; clinical outcome; cohort analysis; cutaneous T cell lymphoma; disease exacerbation; follow up; graft versus host reaction; hematopoietic stem cell transplantation; human; Kaplan Meier method; major clinical study; male; middle aged; multicenter study; observational study; overall survival; propensity score; prospective study; relapse; retrospective study; small cell lung cancer; aged; clinical trial; cutaneous T cell lymphoma; female; mortality; propensity score; skin tumor; Spain; therapy

Compartir